Argenx to stop clinical development of efgartigimod for AAV
Argenx has decided not to go ahead with its development plans for efgartigimod as a potential treatment for ANCA-associated vasculitis (AAV) after the therapy failed to show beneficial effects in late-stage clinical trials of two other autoimmune diseases. Efgartigimod is approved in the U.S. in two formulations for…